ArticlePulmonary pharmacology & therapeutics2021
Fibrinolytic or anti-plasmin (nafamostat) therapy for COVID-19: A timing challenge for clinicians.
Hong-Long Ji et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it